TPMT (Thiopurine S-methyltransferase) variants and mutations
TPMT (also known as Thiopurine S-methyltransferase) is a human protein-coding gene encoding a thiopurine S-methyltransferase protein. It methylates and inactivates thiopurine metabolites, strongly influencing how much cytotoxic thioguanine nucleotide accumulates during therapy. Reduced-function alleles can cause profound myelosuppression at standard thiopurine doses, making genotype or enzyme activity clinically actionable. This analysis covers 388 TPMT variants and mutations. Of these, 96% have computational variant effect predictions. Disease context includes thiopurine S-methyltransferase deficiency, aging, and neurodegenerative disease. Example TPMT variants include G3D, G3S, and T4S.
Variant analysis overview
- Gene: TPMT
- Protein: Thiopurine S-methyltransferase
- UniProt accession: P51580
- Organism: Homo sapiens
- Variants analyzed: 388
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 256 unspecified-consequence records; 1 stop retained variant; 14 frameshift variants; 37 synonymous variants; 73 missense variants; 1 stop-gained variants; 1 in-frame deletions; 3 splice-region variants; 2 in-frame insertions
- Prediction scores: 373 variants have prediction scores (96% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: thiopurine S-methyltransferase deficiency, aging, neurodegenerative disease, inborn errors of metabolism, cancer, autoimmune disorder of central nervous system, atrial fibrillation, Decreased total leukocyte count, acute lymphoblastic leukemia, atrial flutter, malignant colon neoplasm, colonic neoplasm.
Protein structure and variant hotspots
- Protein features: 6 binding sites; 2 post-translational modification sites.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TPMT variants
Examples include G3D, G3S, T4S, R5S, D9N, I10M, I10S, I10V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- G3D (p.Gly3Asp), ESP rs143125661, ExAC rs143125661, TOPMed rs143125661, gnomAD rs143125661, REVEL 0.13, CADD 0.00
- G3S (p.Gly3Ser), TOPMed rs1784302813, gnomAD rs1784302813, REVEL 0.10, CADD 1.57
- T4S (p.Thr4Ser), gnomAD rs1443281341, REVEL 0.21, CADD 0.00
- R5S (p.Arg5Ser), TOPMed rs1784302465, REVEL 0.12, CADD 5.43
- D9N (p.Asp9Asn), Ensembl rs931453225, MetaLR 0.16, MetaSVM -0.87
- I10M (p.Ile10Met), ESP rs200780293, ExAC rs200780293, TOPMed rs200780293, gnomAD rs200780293, REVEL 0.23, CADD 1.59
- I10S (p.Ile10Ser), gnomAD rs1282754346, REVEL 0.19, CADD 6.15
- I10V (p.Ile10Val), Ensembl rs1784302243, MetaLR 0.13, MetaSVM -1.00
- E11K (p.Glu11Lys), TOPMed rs1784301907, REVEL 0.18, CADD 0.02
- E12D (p.Glu12Asp), NCI-TCGA Cosmic COSV1000, NCI-TCGA Cosmic COSV5942, MetaLR 0.42, MetaSVM -0.07, Variant assessed as somatic; moderate impact.
- Y13C (p.Tyr13Cys), gnomAD rs1275757875, REVEL 0.15, CADD 15.10
- S14L (p.Ser14Leu), rs762507236, ClinGen CA3650326, ClinVar RCV004470899, ExAC rs762507236, REVEL 0.20, CADD 18.60, Uncertain significance, not specified
- S14W (p.Ser14Trp), ExAC rs762507236, TOPMed rs762507236, gnomAD rs762507236, MetaLR 0.09, MetaSVM -1.02, Uncertain significance
- D15A (p.Asp15Ala), TOPMed rs948295693, gnomAD rs948295693, REVEL 0.18, CADD 16.60
- D15Y (p.Asp15Tyr), ExAC rs771278148, gnomAD rs771278148, REVEL 0.34, CADD 6.04
- T16I (p.Thr16Ile), ExAC rs747615886, TOPMed rs747615886, gnomAD rs747615886, REVEL 0.18, CADD 5.14
- T16S (p.Thr16Ser), ExAC rs747615886, TOPMed rs747615886, gnomAD rs747615886, REVEL 0.14, CADD 2.26
- E17A (p.Glu17Ala), Ensembl rs751967904
- E17K (p.Glu17Lys), rs772470049, ExAC rs772470049, TOPMed rs772470049, gnomAD rs772470049, REVEL 0.28, CADD 21.20, Variant assessed as somatic; moderate impact.
- E17Q (p.Glu17Gln), rs772470049, ExAC rs772470049, TOPMed rs772470049, gnomAD rs772470049, REVEL 0.34, CADD 22.80, Variant assessed as somatic; moderate impact.
- V18G (p.Val18Gly), Ensembl rs1582048159, MetaLR 0.10, MetaSVM -0.92
- K20E (p.Lys20Glu), rs1438651791, ClinGen CA362840020, ClinVar RCV004321414, TOPMed rs1438651791, REVEL 0.14, CADD 21.40, Uncertain significance, not specified
- N21K (p.Asn21Lys), ExAC rs779065769, TOPMed rs779065769, gnomAD rs779065769, REVEL 0.14, CADD 17.60
- L24P (p.Leu24Pro), ExAC rs755215484, gnomAD rs755215484, REVEL 0.40, CADD 26.20
- T25N (p.Thr25Asn), gnomAD rs1163704950, REVEL 0.10, CADD 22.70
- L26P (p.Leu26Pro), gnomAD rs1784299755, REVEL 0.44, CADD 24.10
- E27K (p.Glu27Lys), Ensembl rs1784299672
- E28Q (p.Glu28Gln), NCI-TCGA Cosmic COSV5942, Variant assessed as somatic; moderate impact.
- E28V (p.Glu28Val), Ensembl rs72552742, MetaLR 0.26, MetaSVM -0.65
- W29* (p.Trp29Ter), TOPMed rs1784299504
- Q30R (p.Gln30Arg), NCI-TCGA Cosmic COSV5943, Variant assessed as somatic; moderate impact.
- K32R (p.Lys32Arg), ExAC rs780247688, gnomAD rs780247688, MetaLR 0.47, MetaSVM 0.11
- W33G (p.Trp33Gly), Ensembl rs72552741, MetaLR 0.60, MetaSVM 0.44
- V34M (p.Val34Met), gnomAD rs1246323577, REVEL 0.22, CADD 22.80
- G36D (p.Gly36Asp), TOPMed rs1207054487, gnomAD rs1207054487, REVEL 0.17, CADD 0.01
- G36S (p.Gly36Ser), rs750424422, NCI-TCGA Cosmic COSV5943, ExAC rs750424422, TOPMed rs750424422, REVEL 0.13, CADD 3.69, Variant assessed as somatic; moderate impact.
- K37M (p.Lys37Met), NCI-TCGA TCGA novel, MetaLR 0.20, MetaSVM -0.74, Variant assessed as somatic; moderate impact.
- K37N (p.Lys37Asn), NCI-TCGA TCGA novel, REVEL 0.17, CADD 0.00, Variant assessed as somatic; moderate impact.
- T38I (p.Thr38Ile), gnomAD rs1784298622, REVEL 0.18, CADD 0.62
- F40L (p.Phe40Leu), gnomAD rs1446592306, REVEL 0.78, CADD 23.60
- F40S (p.Phe40Ser), 1000Genomes rs200695400, MetaLR 0.72, MetaSVM 0.67
- H41R (p.His41Arg), ExAC rs757081801, TOPMed rs757081801, gnomAD rs757081801, REVEL 0.75, CADD 24.90
- E43D (p.Glu43Asp), rs200148021, ClinGen CA3650309, ClinVar RCV004251840, ExAC rs200148021, REVEL 0.10, CADD 14.70, Uncertain significance, not specified
- Q44R (p.Gln44Arg), rs763783722, ClinGen CA3650308, ClinVar RCV004329021, ExAC rs763783722, REVEL 0.06, CADD 18.30, Uncertain significance, not specified
- G45R (p.Gly45Arg), rs2533958330, ClinGen CA362839548, ClinVar RCV004470897, Uncertain significance, not specified
- H46R (p.His46Arg), ExAC rs762702707, gnomAD rs762702707, REVEL 0.45, CADD 27.60
- Q47H (p.Gln47His), TOPMed rs1325058326, gnomAD rs1325058326, REVEL 0.14, CADD 23.60
- L49* (p.Leu49Ter), TOPMed rs72552740
- L49S (p.Leu49Ser), rs72552740, UniProt VAR 005636, TOPMed rs72552740, REVEL 0.69, CADD 25.40, Benign
- K51N (p.Lys51Asn), Ensembl rs1561891928, REVEL 0.22, CADD 21.10
- H52D (p.His52Asp), ExAC rs757971326, gnomAD rs757971326, REVEL 0.54, CADD 23.00
- H52R (p.His52Arg), ExAC rs752440908, gnomAD rs752440908, REVEL 0.60, CADD 24.60
- L53S (p.Leu53Ser), TOPMed rs1322917326
- D54Y (p.Asp54Tyr), NCI-TCGA Cosmic COSV1000, Variant assessed as somatic; moderate impact.
- T55I (p.Thr55Ile), TOPMed rs1392348310, gnomAD rs1392348310, REVEL 0.22, CADD 21.70
- T55P (p.Thr55Pro), ExAC rs759043462, gnomAD rs759043462, REVEL 0.33, CADD 17.90
- F56L (p.Phe56Leu), gnomAD rs1194645282, REVEL 0.10, CADD 19.20
- G59D (p.Gly59Asp), ExAC rs767954730, gnomAD rs767954730, REVEL 0.10, CADD 6.36
- G62E (p.Gly62Glu), 1000Genomes rs558456218, ExAC rs558456218, gnomAD rs558456218
- G62R (p.Gly62Arg), ExAC rs762310024, gnomAD rs762310024, REVEL 0.28, CADD 21.70
- L63M (p.Leu63Met), 1000Genomes rs540172293, ExAC rs540172293, gnomAD rs540172293, REVEL 0.34, CADD 20.90
- L63P (p.Leu63Pro), gnomAD rs1213272472
- R64S (p.Arg64Ser), 1000Genomes rs199762828, ExAC rs199762828, TOPMed rs199762828, REVEL 0.52, CADD 18.10
- V65L (p.Val65Leu), ExAC rs781428057, gnomAD rs781428057, REVEL 0.39, CADD 13.60
- F66I (p.Phe66Ile), gnomAD rs1236222449, REVEL 0.50, CADD 25.60
- F66L (p.Phe66Leu), gnomAD rs1236222449, REVEL 0.22, CADD 24.60
- P68L (p.Pro68Leu), TOPMed rs1368439131, gnomAD rs1368439131, REVEL 0.74, CADD 25.70
- P68S (p.Pro68Ser), Ensembl rs1784276391, MetaLR 0.85, MetaSVM 0.85
- L69F (p.Leu69Phe), 1000Genomes rs200591577, ExAC rs200591577, TOPMed rs200591577, gnomAD rs200591577, REVEL 0.60, CADD 26.50
- L69V (p.Leu69Val), 1000Genomes rs200591577, ExAC rs200591577, TOPMed rs200591577, gnomAD rs200591577, REVEL 0.53, CADD 24.70
- C70* (p.Cys70Ter), 1000Genomes rs186214874, ExAC rs186214874, TOPMed rs186214874, gnomAD rs186214874, Uncertain significance
- C70W (p.Cys70Trp), 1000Genomes rs186214874, ExAC rs186214874, TOPMed rs186214874, gnomAD rs186214874, MetaLR 0.88, MetaSVM 0.99, Uncertain significance
- G71R (p.Gly71Arg), ExAC rs777686348, TOPMed rs777686348, gnomAD rs777686348, REVEL 0.90, CADD 28.80
- A73S (p.Ala73Ser), TOPMed rs1288593258, MetaLR 0.17, MetaSVM -0.79
- A73V (p.Ala73Val), ExAC rs281874771, TOPMed rs281874771, gnomAD rs281874771, REVEL 0.54, CADD 29.30
- E75K (p.Glu75Lys), ExAC rs778578091, gnomAD rs778578091, REVEL 0.68, CADD 27.80
- M76I (p.Met76Ile), ExAC rs754599894, gnomAD rs754599894, REVEL 0.58, CADD 27.00
- M76K (p.Met76Lys), TOPMed rs1200214781, gnomAD rs1200214781, REVEL 0.84, CADD 27.00
- K77E (p.Lys77Glu), Ensembl rs1561891831, REVEL 0.31, CADD 28.50
- W78* (p.Trp78Ter), TOPMed rs1393608525, gnomAD rs1393608525, CADD 57.00
- W78C (p.Trp78Cys), rs1256618794, ClinGen CA362838562, ClinVar RCV000766276, TOPMed rs1256618794, REVEL 0.81, CADD 34.00, drug response, Thiopurine response
- W78L (p.Trp78Leu), TOPMed rs1393608525, gnomAD rs1393608525, MetaLR 0.71, MetaSVM 0.64
- W78R (p.Trp78Arg), ExAC rs753277177, gnomAD rs753277177, REVEL 0.88, CADD 33.00
- F79L (p.Phe79Leu), Ensembl rs1784193428, MetaLR 0.33, MetaSVM -0.34
- A80P (p.Ala80Pro), rs1800462, ClinGen CA122644, ClinVar RCV000013558, UniProt VAR 005637, REVEL 0.85, CADD 24.60, drug response, Thiopurine S-methyltransferase deficiency
- A80V (p.Ala80Val), 1000Genomes rs190484211, REVEL 0.65, CADD 27.60
- R82G (p.Arg82Gly), ESP rs111901354, ExAC rs111901354, TOPMed rs111901354, gnomAD rs111901354, REVEL 0.43, CADD 23.00
- R82L (p.Arg82Leu), NCI-TCGA Cosmic COSV5942, Variant assessed as somatic; moderate impact.
- R82P (p.Arg82Pro), NCI-TCGA Cosmic COSV5942, REVEL 0.55, CADD 21.90, Variant assessed as somatic; moderate impact.
- R82Q (p.Arg82Gln), ESP rs142214108, ExAC rs142214108, TOPMed rs142214108, gnomAD rs142214108, REVEL 0.14, CADD 16.30, Uncertain significance, not specified
- R82W (p.Arg82Trp), ESP rs111901354, ExAC rs111901354, TOPMed rs111901354, gnomAD rs111901354, REVEL 0.73, CADD 25.40
- G83V (p.Gly83Val), TOPMed rs1293957844, gnomAD rs1293957844, REVEL 0.87, CADD 25.80
- H84D (p.His84Asp), gnomAD rs1235431245, REVEL 0.57, CADD 26.50
- H84L (p.His84Leu), Ensembl rs1582044292
- S85G (p.Ser85Gly), Ensembl rs1044039224
- S85N (p.Ser85Asn), NCI-TCGA TCGA novel, MetaLR 0.11, MetaSVM -1.02, Variant assessed as somatic; moderate impact.
- S85T (p.Ser85Thr), TOPMed rs1457901774, gnomAD rs1457901774, REVEL 0.05, CADD 8.19
- G88C (p.Gly88Cys), ExAC rs753545734, TOPMed rs753545734, gnomAD rs753545734, REVEL 0.89, CADD 26.70, Drug response
- G88S (p.Gly88Ser), rs753545734, ClinGen CA362838473, ClinVar RCV000766277, ExAC rs753545734, REVEL 0.91, CADD 28.50, drug response, Thiopurine response
- V89E (p.Val89Glu), TOPMed rs1784191846
- E90V (p.Glu90Val), TOPMed rs1681788109, MetaLR 0.56, MetaSVM 0.32
- I91M (p.Ile91Met), TOPMed rs1399023154, gnomAD rs1399023154, REVEL 0.51, CADD 24.30
- E93D (p.Glu93Asp), NCI-TCGA TCGA novel, MetaLR 0.39, MetaSVM -0.40, Variant assessed as somatic; moderate impact.
- G95V (p.Gly95Val), NCI-TCGA TCGA novel, MetaLR 0.35, MetaSVM -0.21, Variant assessed as somatic; moderate impact.
- I96M (p.Ile96Met), gnomAD rs1369827450, MetaLR 0.07, MetaSVM -1.02
- Q97* (p.Gln97Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q97R (p.Gln97Arg), TOPMed rs1296990696, gnomAD rs1296990696, REVEL 0.08, CADD 6.15
- E98* (p.Glu98Ter), rs72552739, ESP rs72552739, ExAC rs72552739, TOPMed rs72552739, CADD 41.00, Uncertain significance
- E98D (p.Glu98Asp), rs755583154, ClinGen CA3650240, ClinVar RCV004470898, ExAC rs755583154, REVEL 0.10, CADD 18.10, Uncertain significance, not specified
- F99L (p.Phe99Leu), TOPMed rs1784190885, MetaLR 0.49, MetaSVM 0.22
- N104T (p.Asn104Thr), gnomAD rs1784190607, MetaLR 0.29, MetaSVM -0.44
- L105R (p.Leu105Arg), TOPMed rs1474060016, gnomAD rs1474060016, REVEL 0.77, CADD 27.70
- L105V (p.Leu105Val), Ensembl rs895534962
- S106F (p.Ser106Phe), ExAC rs764606523, gnomAD rs764606523, REVEL 0.28, CADD 25.70
- Y107* (p.Tyr107Ter), ExAC rs753105368, gnomAD rs753105368
- E109D (p.Glu109Asp), TOPMed rs1322032816
- E109G (p.Glu109Gly), NCI-TCGA Cosmic COSV1000, MetaLR 0.39, MetaSVM -0.46, Variant assessed as somatic; moderate impact.
- E109K (p.Glu109Lys), gnomAD rs1248105963, REVEL 0.38, CADD 24.30
- E109V (p.Glu109Val), gnomAD rs1195203273, REVEL 0.54, CADD 32.00
- P111R (p.Pro111Arg), ExAC rs765582677, gnomAD rs765582677, REVEL 0.18, CADD 23.50
- P111S (p.Pro111Ser), NCI-TCGA TCGA novel, Ensembl rs1784189914, REVEL 0.12, CADD 20.80, Variant assessed as somatic; moderate impact.
- I112N (p.Ile112Asn), Ensembl rs886061266, MetaLR 0.42, MetaSVM -0.43, Uncertain significance
- E114K (p.Glu114Lys), rs115106679, NCI-TCGA Cosmic COSV5943, 1000Genomes rs115106679, ExAC rs115106679, REVEL 0.71, CADD 22.40, Variant assessed as somatic; moderate impact.
- I115T (p.Ile115Thr), TOPMed rs934835159, gnomAD rs934835159, REVEL 0.34, CADD 25.30
- P116A (p.Pro116Ala), TOPMed rs1479488394, gnomAD rs1479488394, REVEL 0.08, CADD 17.30
- G117R (p.Gly117Arg), TOPMed rs1183234651, gnomAD rs1183234651, REVEL 0.59, CADD 26.40
- K119N (p.Lys119Asn), Ensembl rs769846188, MetaLR 0.48, MetaSVM 0.00
- K119T (p.Lys119Thr), ESP rs151149760, ExAC rs151149760, TOPMed rs151149760, gnomAD rs151149760, REVEL 0.55, CADD 26.70
- S123N (p.Ser123Asn), gnomAD rs1330046697, REVEL 0.15, CADD 19.10
- S124Y (p.Ser124Tyr), NCI-TCGA Cosmic COSV5942, Ensembl rs1784108274, REVEL 0.36, CADD 29.80, Variant assessed as somatic; moderate impact.
- S125L (p.Ser125Leu), 1000Genomes rs200220210, ESP rs200220210, ExAC rs200220210, TOPMed rs200220210, REVEL 0.21, CADD 26.70
- S125S (p.Ser125Ser), gnomAD 6-18139709-C-A, CADD 2.29, SIFT 0.02
- S125P (p.Ser125Pro), gnomAD 6-18139711-A-G, REVEL 0.28, MetaLR 0.14
- G126A (p.Gly126Ala), ExAC rs773335632, TOPMed rs773335632, gnomAD rs773335632, REVEL 0.51, CADD 24.00, Uncertain significance, not specified
- G126E (p.Gly126Glu), ExAC rs773335632, TOPMed rs773335632, gnomAD rs773335632, Uncertain significance
- G126R (p.Gly126Arg), 1000Genomes rs200917792, REVEL 0.51, CADD 22.40
- G126G (p.Gly126Gly), gnomAD 6-18139706-C-A, CADD 16.10
- N127S (p.Asn127Ser), TOPMed rs1340845395, gnomAD rs1340845395, REVEL 0.14, CADD 16.90
- N127N (p.Asn127Asn), rs1435127761, gnomAD 6-18139703-G-A, CADD 5.91, SIFT 0.02
- N127E (p.Asn127Glu), rs1157568159, gnomAD 6-18139705-T-TC, CADD 32.00
- I128V (p.Ile128Val), TOPMed rs1217971473, REVEL 0.33, CADD 23.80
- I128L (p.Ile128Leu), gnomAD 6-18139702-T-G, REVEL 0.45, MetaLR 0.42
- S129L (p.Ser129Leu), NCI-TCGA Cosmic COSV5942, MetaLR 0.14, MetaSVM -0.84, Variant assessed as somatic; moderate impact.
- S129P (p.Ser129Pro), gnomAD rs1396619437, REVEL 0.42, CADD 24.00
- L130L (p.Leu130Leu), rs1784107642, gnomAD 6-18139694-C-T, CADD 10.50, SIFT 0.29
- L130F (p.Leu130Phe), gnomAD 6-18139694-C-A, REVEL 0.68, MetaLR 0.47
- L130W (p.Leu130Trp), gnomAD 6-18139695-A-C, REVEL 0.81, MetaLR 0.64
- L130S (p.Leu130Ser), gnomAD 6-18139695-A-G, REVEL 0.80, MetaLR 0.54
- Y131F (p.Tyr131Phe), gnomAD 6-18139692-T-A, REVEL 0.20, MetaLR 0.18
- Y131H (p.Tyr131His), gnomAD 6-18139693-A-G, REVEL 0.82, MetaLR 0.59
- C132Y (p.Cys132Tyr), TOPMed rs72552738, REVEL 0.67, CADD 23.40
- C132C (p.Cys132Cys), rs1784107597, gnomAD 6-18139688-A-G, CADD 8.71
- C132G (p.Cys132Gly), gnomAD 6-18139690-A-C, REVEL 0.76, MetaLR 0.54
- C132R (p.Cys132Arg), gnomAD 6-18139690-A-G, REVEL 0.76, MetaLR 0.56
- C133W (p.Cys133Trp), rs1276273082, gnomAD 6-18139685-G-GC, CADD 32.00
- C133Y (p.Cys133Tyr), gnomAD 6-18139686-C-T, REVEL 0.73, MetaLR 0.59
- S134G (p.Ser134Gly), Ensembl rs1347019530, REVEL 0.26, CADD 22.80
- S134N (p.Ser134Asn), Ensembl rs1784107463, REVEL 0.14, CADD 1.79
- I135Y (p.Ile135Tyr), gnomAD 6-18139681-T-TA, CADD 32.00
- F136Y (p.Phe136Tyr), gnomAD 6-18139677-A-T, REVEL 0.41, MetaLR 0.46
- D137H (p.Asp137His), rs376217758, ESP rs376217758, ExAC rs376217758, TOPMed rs376217758, AlphaMissense 0.25, MetaLR 0.38, Variant assessed as somatic; moderate impact.
- D137Y (p.Asp137Tyr), rs376217758, ESP rs376217758, ExAC rs376217758, TOPMed rs376217758, REVEL 0.52, AlphaMissense 0.25, Uncertain significance, not specified
- D137G (p.Asp137Gly), gnomAD 6-18139674-T-C, REVEL 0.45, MetaLR 0.31
- D137* (p.Asp137Ter), rs1784107421, gnomAD 6-18139675-C-CA, CADD 33.00
- L138F (p.Leu138Phe), rs372997906, ClinGen CA3650202, ClinVar RCV004187293, ESP rs372997906, REVEL 0.17, CADD 21.20, Likely benign, not specified
- L138I (p.Leu138Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L138H (p.Leu138His), gnomAD 6-18139671-A-T, REVEL 0.81, MetaLR 0.67
- L138V (p.Leu138Val), gnomAD 6-18139672-G-C, REVEL 0.34, MetaLR 0.30
- P139L (p.Pro139Leu), NCI-TCGA TCGA novel, MetaLR 0.12, MetaSVM -0.89, Variant assessed as somatic; moderate impact.
- P139S (p.Pro139Ser), NCI-TCGA Cosmic COSV5942, REVEL 0.08, CADD 17.90, Variant assessed as somatic; moderate impact.
- P139T (p.Pro139Thr), gnomAD 6-18139669-G-T, REVEL 0.08, MetaLR 0.08
- R140K (p.Arg140Lys), ExAC rs768603346, gnomAD rs768603346, REVEL 0.14, CADD 33.00
- R140R (p.Arg140Arg), gnomAD 6-18139037-C-T, CADD 11.80, SIFT 0.51
- R140G (p.Arg140Gly), gnomAD 6-18139666-T-C, REVEL 0.27, MetaLR 0.22
- T141I (p.Thr141Ile), ExAC rs775254609, gnomAD rs775254609, REVEL 0.12, CADD 14.70
- T141T (p.Thr141Thr), gnomAD 6-18139034-T-C, CADD 5.33, SIFT 0.04
- I143T (p.Ile143Thr), ExAC rs769630417, gnomAD rs769630417, REVEL 0.29, CADD 23.40
- I143V (p.Ile143Val), TOPMed rs1784092655, MetaLR 0.36, MetaSVM -0.43
- G144R (p.Gly144Arg), Ensembl rs72552737
- G144G (p.Gly144Gly), gnomAD 6-18139025-G-C, CADD 9.26, SIFT 0.01
Public TPMT analysis runs
- TPMT analysis run — TPMT (388 variants) — completed 2026-08-10